Bamco Inc. NY Has $48.26 Million Position in Teladoc Inc (TDOC)
Bamco Inc. NY increased its stake in shares of Teladoc Inc (NYSE:TDOC) by 751.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,455,900 shares of the health services provider’s stock after acquiring an additional 1,285,000 shares during the period. Bamco Inc. NY owned about 2.56% of Teladoc worth $48,263,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ETF Managers Group LLC bought a new stake in Teladoc during the second quarter worth about $104,000. Bank of Montreal Can raised its stake in Teladoc by 214.2% in the second quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after buying an additional 2,397 shares during the period. Pacad Investment Ltd. bought a new stake in Teladoc in the second quarter valued at approximately $135,000. Fred Alger Management Inc. bought a new stake in Teladoc in the second quarter valued at approximately $139,000. Finally, Ameritas Investment Partners Inc. raised its stake in Teladoc by 134.2% in the second quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after buying an additional 2,707 shares during the period.
In other news, VP Mark Hirschhorn sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $34.04, for a total value of $340,400.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jason N. Gorevic sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $33.47, for a total value of $669,400.00. The disclosure for this sale can be found here. Insiders sold 265,000 shares of company stock worth $8,697,400 in the last ninety days. 4.47% of the stock is owned by company insiders.
Teladoc Inc (NYSE:TDOC) traded down $1.25 during trading on Tuesday, hitting $32.30. The stock had a trading volume of 631,900 shares, compared to its average volume of 969,216. Teladoc Inc has a 52 week low of $15.65 and a 52 week high of $37.90. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08.
Teladoc (NYSE:TDOC) last posted its earnings results on Wednesday, November 1st. The health services provider reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.25). Teladoc had a negative net margin of 39.61% and a negative return on equity of 21.59%. The firm had revenue of $68.70 million during the quarter, compared to analyst estimates of $67.53 million. During the same period in the previous year, the company posted ($0.33) EPS. Teladoc’s revenue for the quarter was up 112.0% compared to the same quarter last year. analysts anticipate that Teladoc Inc will post -1.57 EPS for the current year.
Several analysts have issued reports on the company. Cantor Fitzgerald restated a “hold” rating and issued a $31.00 price objective on shares of Teladoc in a research note on Tuesday, September 26th. Cowen restated an “outperform” rating and issued a $39.00 price objective on shares of Teladoc in a research note on Saturday, September 30th. BidaskClub upgraded Teladoc from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. CIBC restated an “outperform” rating and issued a $45.00 price objective (up previously from $40.00) on shares of Teladoc in a research note on Tuesday, November 21st. Finally, Zacks Investment Research upgraded Teladoc from a “sell” rating to a “buy” rating and set a $38.00 price objective on the stock in a research note on Wednesday, October 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $39.15.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Inc (NYSE:TDOC).
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with Analyst Ratings Network's FREE daily email newsletter.